Johnson & Johnson/$JNJ
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Employees
138,100
Headquarters
Website
JNJ Metrics
BasicAdvanced
$587B
22.07
$11.03
0.35
$5.14
2.14%
Price and volume
Market cap
$587B
Beta
0.35
52-week high
$246.35
52-week low
$141.50
Average daily volume
9.4M
Dividend rate
$5.14
Financial strength
Total debt to equity
57.766
Profitability
EBITDA (TTM)
33,059.665
Gross margin (TTM)
68.07%
Net profit margin (TTM)
28.46%
Operating margin (TTM)
27.32%
Effective tax rate (TTM)
17.73%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on equity (TTM)
35.56%
Valuation
Price to earnings (TTM)
22.072
Price to revenue (TTM)
6.279
Price to book
7.39
Price to tangible book (TTM)
-33.46
Dividend yield (TTM)
2.11%
Forward dividend yield
2.14%
Growth
Revenue change (TTM)
6.05%
Earnings per share change (TTM)
90.50%
3-year revenue growth (CAGR)
5.60%
10-year revenue growth (CAGR)
3.00%
3-year earnings per share growth (CAGR)
17.90%
10-year earnings per share growth (CAGR)
7.25%
3-year dividend per share growth (CAGR)
4.92%
10-year dividend per share growth (CAGR)
5.71%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial
Business Wire·16 hours ago
Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K
New York Post·16 hours ago
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
Reuters·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $587B as of February 14, 2026.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 22.07 as of February 14, 2026.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of February 14, 2026, the dividend rate is $5.14 and the yield is 2.14%. Johnson & Johnson has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment is scheduled for March 10, 2026.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.